Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 19/20 | 0.57 |
| ▸ | CA1 | P00915 | 14/20 | 0.57 |
| ▸ | CA9 | Q16790 | 11/20 | 0.57 |
| ▸ | CA12 | O43570 | 8/20 | 0.57 |
| ▸ | CA7 | P43166 | 7/20 | 0.57 |
| ▸ | CA5A | P35218 | 6/20 | 0.57 |
| ▸ | CA5B | Q9Y2D0 | 6/20 | 0.57 |
| ▸ | CA4 | P22748 | 5/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.57 |
| ▸ | CA6 | P23280 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2475122 | 0.79 | CA2 (0.61) | CA2CA1CA9CA12CA7 | |
| SCHEMBL16296148 | 0.79 | CA2 (0.61) | CA2CA1CA9CA12CA7 | |
| SCHEMBL216845 | 0.76 | CA2 (0.64) | CA2CA1CA9CA12CA7 | |
| SCHEMBL309694 | 0.75 | CA2 (0.73) | CA2CA1CA9CA12CA7 | |
| SCHEMBL24391565 | 0.75 | CA2 (0.55) | CA2CA1CA9CA12CA7 | |
| SCHEMBL202948 | 0.74 | CA2 (0.81) | CA2CA1CA9CA12CA7 | |
| Mafenide SCHEMBL41628 | 0.73 | CA2 (1.00) | CA2CA1CA9CA12CA7 | |
| Mafenide SCHEMBL9295695 | 0.73 | CA2 (1.00) | CA2CA1CA9CA12CA7 | |
| SCHEMBL1804376 | 0.73 | CA2 (0.67) | CA2CA1CA9CA12CA7 | |
| Sulfamide SCHEMBL5585371 | 0.73 | CA2 (0.70) | CA2CA1CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373622-A2 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | Molecular Insight Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010065906-A2 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |